5 Comments
Jul 30, 2023Liked by Elliot Hershberg

Elliot, great piece! Would love to hear to your thoughts on the clinical trial bottleneck and potential solutions/companies that are tackling this massive problem. I really think solving the clinical trial problem will allow for a complete realignment of the pharmaceutical/biotech industry around transformational therapies, preventative medicine, and a focus on the health afflictions of the many not just the rare diseases of the few (still important).

Expand full comment
author

Thanks, Nikhil. I couldn't have asked for better timing for this question! I hope you enjoy my new essay on Vial:

https://centuryofbio.com/p/vial

This is an incredibly important area, and likely won't be the last post I write about it.

Expand full comment
Jun 5, 2023Liked by Elliot Hershberg

During the last biotech boom in the 2000s I read where a consortium (or was it just Germany?) we're essentially building a human body with software that could simulate how novel drugs would interact and thereby sidestep some of the "clinical bottleneck". I haven't really heard much about it since--Im sure it was way to complex to tackle 20 years ago, probably even today, but is anyone working along these lines?

Expand full comment
Jul 30, 2023Liked by Elliot Hershberg

Unlearn.ai is tackling a part of of this problem by creating digital twins for use as the control arm of studies.

Expand full comment
Jul 30, 2023Liked by Elliot Hershberg

And it looks like they can bypass a generalized physiology and go straight to twins for individuals, wow!

Expand full comment